Skip to content
10-Q

Quarterly Report

SUTRO BIOPHARMA, INC. STRO

0000950170-25-067072

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 2, 2025 84.46M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $133.05M
Current Liabilities Q1 2025 · Dec 31, 2024 $131.89M
Total Liabilities Q1 2025 · Mar 31, 2025 $347.24M
Total Liabilities Q1 2025 · Dec 31, 2024 $342.61M
Current Assets Q1 2025 · Mar 31, 2025 $287.41M
Current Assets Q1 2025 · Dec 31, 2024 $343.31M
Total Assets Q1 2025 · Mar 31, 2025 $321.43M
Total Assets Q1 2025 · Dec 31, 2024 $387.21M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $190.3M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $65.22M
Shares Diluted Q1 2025 · Mar 31, 2024 61.46M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$64.74M
Stockholders Equity Q1 2025 · Mar 31, 2024 $98.02M
Stockholders Equity Q1 2025 · Dec 31, 2023 $149.65M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.95
Eps Basic Q1 2025 · Mar 31, 2024 −$0.95
Sga Expense Q1 2025 · Mar 31, 2024 $12.72M
Rd Expense Q1 2025 · Mar 31, 2024 $56.88M
Net Income Q1 2025 · Mar 31, 2024 −$58.21M
Operating Income Q1 2025 · Mar 31, 2024 −$56.59M
Revenue Q1 2025 · Mar 31, 2024 $13.01M